mifepristone has been researched along with asoprisnil in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, AL; Adams, WR; Berrodin, TJ; Cohen, J; Fensome, A; Hudak, VA; Huselton, C; Illenberger, A; Kern, JC; Marella, MA; McComas, CC; Melenski, EG; Mugford, CA; Slayden, OD; Winneker, RC; Wrobel, JE; Yudt, M; Zhang, P; Zhang, Z; Zhu, Y | 1 |
| Bleisch, TJ; Clarke, CA; Dodge, JA; Galvin, RJ; Geiser, AG; Hughes, NE; Jones, SA; Lopez, JE; Lugar, CW; Montrose-Rafizadeh, C; Moore, TL; Muehl, BS; Osborne, JJ; Patel, N; Richardson, TI; Shetler, PK; Yee, YK; Yu, KL; Zink, RW | 1 |
| Bray, J; Edwards, R; Laping, N; Pullen, MA | 1 |
| Harkins, RN; Jin, F; Levitsky, K; Meurer-Ogden, JA; Szymanski, P | 1 |
| Spitz, IM | 1 |
| Csatlós, E; Joó, JG; Nagy, Z; Rigó, J; Szabó, I | 1 |
| Sarkar, NN | 1 |
| Azevedo, R; Bosch, R; de Vlieg, J; Dechering, K; Hamersma, H; Kazemier, B; Lusher, SJ; McGuire, R; Oubrie, A; Raaijmakers, HC; van Duin, M; Vu-Pham, D | 1 |
| Manyonda, I; Talaulikar, VS | 1 |
| Bastianelli, C; Benagiano, G; Brosens, I; Farris, M | 1 |
| Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
| Centini, G; Kashani, BN; Morelli, SS; Petraglia, F; Weiss, G | 1 |
| Chow, TL; Murji, A; Sobel, ML; Whitaker, L | 1 |
| Chen, H; Fu, J; Huang, W; Song, H; Wang, Y; Zhou, M; Zhu, H | 1 |
| Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S | 1 |
9 review(s) available for mifepristone and asoprisnil
| Article | Year |
|---|---|
Clinical utility of progesterone receptor modulators and their effect on the endometrium.
Topics: Drug Administration Schedule; Endometriosis; Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Randomized Controlled Trials as Topic; Receptors, Progesterone; Time Factors; Uterine Neoplasms | 2009 |
[Uterine leiomyoma].
Topics: Antineoplastic Agents; Diagnosis, Differential; Estrenes; Female; Hormone Antagonists; Humans; Hysterectomy; Incidence; Laparoscopy; Leiomyoma; Mifepristone; Oximes; Ultrasonic Therapy; Uterine Artery; Uterine Neoplasms | 2010 |
Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
Topics: Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Hyperplasia; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone | 2012 |
Selective progesterone receptor modulators: an update.
Topics: Adenomyosis; Animals; Clinical Trials as Topic; Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Endometriosis; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone; Uterine Neoplasms | 2014 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
Role of Medical Management for Uterine Leiomyomas.
Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Cabergoline; Cholecalciferol; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Danazol; Dopamine Agonists; Ergolines; Estrenes; Estrogen Antagonists; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Patient Care Planning; Selective Estrogen Receptor Modulators; Somatostatin; Tranexamic Acid; Uterine Neoplasms; Vitamins | 2016 |
Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Topics: Amenorrhea; Antineoplastic Agents, Hormonal; Estrenes; Female; Humans; Leiomyoma; Leuprolide; Menstruation; Mifepristone; Norpregnadienes; Oximes; Pelvic Pain; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2017 |
Progesterone receptor modulators for endometriosis.
Topics: Danazol; Dysmenorrhea; Dyspareunia; Endometriosis; Estrenes; Female; Gestrinone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Leuprolide; Mifepristone; Norpregnadienes; Oximes; Prevalence; Randomized Controlled Trials as Topic; Receptors, Progesterone | 2017 |
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms | 2018 |
6 other study(ies) available for mifepristone and asoprisnil
| Article | Year |
|---|---|
Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Indoles; Macaca fascicularis; Macaca mulatta; Molecular Structure; Ovulation; Oxindoles; Pyrroles; Rats; Receptors, Progesterone; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.
Topics: | 2011 |
Determination of conformational changes in the progesterone receptor using ELISA-like assays.
Topics: Animals; Binding, Competitive; Enzyme-Linked Immunosorbent Assay; Estrenes; Female; Mifepristone; Oximes; Protein Binding; Protein Conformation; Rabbits; Receptors, Progesterone; Structure-Activity Relationship; Uterus | 2006 |
Development and validation of an improved inducer-regulator protein complex in the pBRES-regulated expression system.
Topics: Alkaline Phosphatase; Animals; Breast Neoplasms; DNA Primers; Estrenes; Female; Gene Expression Regulation, Neoplastic; Genetic Vectors; Hormone Antagonists; Humans; Luciferases; Mice; Mifepristone; Mutagenesis, Site-Directed; Oximes; Protein Structure, Tertiary; Receptors, Progesterone; Transfection; Transgenes; Tumor Cells, Cultured | 2008 |
The state-of-the-art of emergency contraception with the cutting edge drug.
Topics: Contraception, Postcoital; Contraceptive Agents, Female; Estrenes; Female; Gonanes; Humans; Mifepristone; Norpregnadienes; Oximes; Pregnancy; Receptors, Progesterone | 2011 |
X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.
Topics: Crystallography, X-Ray; Estrenes; Humans; Ligands; Mifepristone; Oximes; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Progesterone | 2012 |